Dear Editor,

We read the article “Cardiac troponin I and creatine kinase MB isoenzyme in patients with chronic renal failure” written by Larry M. Flores-Solís et al. with interest. The authors concluded that the cut-off value proposed in this study for both cardiac troponin I (cTnI) in patients with chronic renal failure (CRF) (stage 3 to 5) to diagnose acute coronary syndrome (ACS) is significantly different from that of the general population. Thank to the authors for their contribution of a study designed and documented successfully. We believe that these findings will guide further studies about cTnI and creatine kinase MB (CK-MB) levels and CRF.

cTnI and CK-MB levels in patients presenting with a suspected acute coronary syndrome help in the diagnosis of patients. It was proposed in a previous study that estimation of the glomerular filtration rate based on a normal creatinine level on admission provided important information on short-term prognosis and also it was recommended that glomerular filtration rate should be included in the risk assessment of patients with normal serum creatinine levels. But there is another issue which is the basement of the present study that patients with high creatinine levels due to CRF may be expected to have elevated cTnI levels due to decreased glomerular filtration. However, cTnI is again the preferred biomarker for myocardial damage in patients with CRF as it is one of the least changed markers. When the patients with an elevated serum creatinine levels, especially those on dialysis treatment, are candidates for increased cardiovascular accidents, it is an additive factor that this situation may lead to some difficulties and can be more problematic in diagnosis of patients with a suspected acute coronary syndrome.

In addition to renal failure, cTnI levels may frequently be measured above normal values in several disease states in which myocardial necrosis is not a prominent aspect, especially in pulmonary embolism, heart failure, liver cirrhosis, septic shock, and arterial hypertension. Our challenge is on the issue that the study would be stronger if all the additional factors that might elevate cTnI levels were mentioned in the study.

Conflicts of interest

The authors declare that they have no conflicts of interest related to the contents of this article.


Sr. Director:

Agradecemos los comentarios y el interés del Dr. Cakar M. y sus colaboradores sobre nuestro estudio titulado «Troponina I cardíaca y creatina cinasa MB en pacientes con insuficiencia renal crónica», en el que incluimos 484 pacientes consecutivos con insuficiencia renal crónica (IRC) y sospecha de síndrome coronario agudo (SCA). Debido a que los pacientes con IRC son una población de alto riesgo cardiovascular, decidimos aplicar una estrategia que permitiera aumentar la sensibilidad diagnóstica y obtuvimos un valor de corte de troponina I cardíaca (TnIc) significativamente diferente del utilizado para la población general para di-

Respuesta al comentario sobre «Cardiac troponin I and creatine kinase MB isoenzyme in patients with chronic renal failure»

Nefrologia 2013;33(6):852-3


Mustafa Cakar1, Sevket Balta2, Omer Kurt1, Murat Unlu2, Seref Demirbas1, Sait Demirkol2
1 Department of Internal Medicine. Gulhane Medical Academy, Ankara (Turkey).
2 Department of Cardiology. Gulhane Medical Academy, Ankara (Turkey).

Correspondencia: Mustafa Cakar
Department of Internal Medicine, Gulhane Medical Academy, Ankara, Turkey.
drmustafacakar@gmail.com